Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension

A controlled trial

Melvyn Rubenfire, Vallerie V. McLaughlin, Roblee P Allen, Greg Elliott, Myung H. Park, Michael Wade, Robert Schilz

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Background: We determined the relative efficacy of subcutaneous (SC) treprostinil in stable World Health Organization class II and III patients transitioned from IV epoprostenol. Methods: This was an 8-week, multicenter, randomized study in which patients were transitioned from IV epoprostenol to SC treprostinil or placebo over a period of up to 14 days and monitored carefully during and after the transition period for signs of deterioration. Patients with clinical deterioration were returned promptly to epoprostenol. Placebo or SC treprostinil doses were titrated in response to symptoms. Time to adjudicated clinical deterioration was compared between treatment groups, and exercise capacity, symptoms of disease, and safety were assessed throughout the study. Results: Twenty-two patients were enrolled and completed the study. Seven of 8 patients (88%) withdrawn to placebo had clinical deterioration, while only 1 of 14 patients (7%) withdrawn to SC treprostinil had clinical deterioration (p = 0.00023 based on a treatment comparison of time to deterioration). Analyses of exercise capacity and symptoms strongly supported the efficacy of SC treprostinil in epoprostenol-treated patients. Adverse events consisted of painful infusion site reactions and anticipated prostacyclin side effects. Conclusions: SC treprostinil is effective in pulmonary arterial hypertension and prevents clinical deterioration and maintains functional status in patients transitioned from epoprostenol.

Original languageEnglish (US)
Pages (from-to)757-763
Number of pages7
JournalChest
Volume132
Issue number3
DOIs
StatePublished - Sep 2007

Fingerprint

Epoprostenol
Pulmonary Hypertension
Placebos
Exercise
treprostinil
Multicenter Studies
Safety
Therapeutics

Keywords

  • Prostacyclin
  • Pulmonary hypertension
  • Withdrawal trial

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension : A controlled trial. / Rubenfire, Melvyn; McLaughlin, Vallerie V.; Allen, Roblee P; Elliott, Greg; Park, Myung H.; Wade, Michael; Schilz, Robert.

In: Chest, Vol. 132, No. 3, 09.2007, p. 757-763.

Research output: Contribution to journalArticle

Rubenfire, M, McLaughlin, VV, Allen, RP, Elliott, G, Park, MH, Wade, M & Schilz, R 2007, 'Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: A controlled trial', Chest, vol. 132, no. 3, pp. 757-763. https://doi.org/10.1378/chest.06-2118
Rubenfire, Melvyn ; McLaughlin, Vallerie V. ; Allen, Roblee P ; Elliott, Greg ; Park, Myung H. ; Wade, Michael ; Schilz, Robert. / Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension : A controlled trial. In: Chest. 2007 ; Vol. 132, No. 3. pp. 757-763.
@article{f8cfd60343234ea6852cbcc5dbecb5db,
title = "Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: A controlled trial",
abstract = "Background: We determined the relative efficacy of subcutaneous (SC) treprostinil in stable World Health Organization class II and III patients transitioned from IV epoprostenol. Methods: This was an 8-week, multicenter, randomized study in which patients were transitioned from IV epoprostenol to SC treprostinil or placebo over a period of up to 14 days and monitored carefully during and after the transition period for signs of deterioration. Patients with clinical deterioration were returned promptly to epoprostenol. Placebo or SC treprostinil doses were titrated in response to symptoms. Time to adjudicated clinical deterioration was compared between treatment groups, and exercise capacity, symptoms of disease, and safety were assessed throughout the study. Results: Twenty-two patients were enrolled and completed the study. Seven of 8 patients (88{\%}) withdrawn to placebo had clinical deterioration, while only 1 of 14 patients (7{\%}) withdrawn to SC treprostinil had clinical deterioration (p = 0.00023 based on a treatment comparison of time to deterioration). Analyses of exercise capacity and symptoms strongly supported the efficacy of SC treprostinil in epoprostenol-treated patients. Adverse events consisted of painful infusion site reactions and anticipated prostacyclin side effects. Conclusions: SC treprostinil is effective in pulmonary arterial hypertension and prevents clinical deterioration and maintains functional status in patients transitioned from epoprostenol.",
keywords = "Prostacyclin, Pulmonary hypertension, Withdrawal trial",
author = "Melvyn Rubenfire and McLaughlin, {Vallerie V.} and Allen, {Roblee P} and Greg Elliott and Park, {Myung H.} and Michael Wade and Robert Schilz",
year = "2007",
month = "9",
doi = "10.1378/chest.06-2118",
language = "English (US)",
volume = "132",
pages = "757--763",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "3",

}

TY - JOUR

T1 - Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension

T2 - A controlled trial

AU - Rubenfire, Melvyn

AU - McLaughlin, Vallerie V.

AU - Allen, Roblee P

AU - Elliott, Greg

AU - Park, Myung H.

AU - Wade, Michael

AU - Schilz, Robert

PY - 2007/9

Y1 - 2007/9

N2 - Background: We determined the relative efficacy of subcutaneous (SC) treprostinil in stable World Health Organization class II and III patients transitioned from IV epoprostenol. Methods: This was an 8-week, multicenter, randomized study in which patients were transitioned from IV epoprostenol to SC treprostinil or placebo over a period of up to 14 days and monitored carefully during and after the transition period for signs of deterioration. Patients with clinical deterioration were returned promptly to epoprostenol. Placebo or SC treprostinil doses were titrated in response to symptoms. Time to adjudicated clinical deterioration was compared between treatment groups, and exercise capacity, symptoms of disease, and safety were assessed throughout the study. Results: Twenty-two patients were enrolled and completed the study. Seven of 8 patients (88%) withdrawn to placebo had clinical deterioration, while only 1 of 14 patients (7%) withdrawn to SC treprostinil had clinical deterioration (p = 0.00023 based on a treatment comparison of time to deterioration). Analyses of exercise capacity and symptoms strongly supported the efficacy of SC treprostinil in epoprostenol-treated patients. Adverse events consisted of painful infusion site reactions and anticipated prostacyclin side effects. Conclusions: SC treprostinil is effective in pulmonary arterial hypertension and prevents clinical deterioration and maintains functional status in patients transitioned from epoprostenol.

AB - Background: We determined the relative efficacy of subcutaneous (SC) treprostinil in stable World Health Organization class II and III patients transitioned from IV epoprostenol. Methods: This was an 8-week, multicenter, randomized study in which patients were transitioned from IV epoprostenol to SC treprostinil or placebo over a period of up to 14 days and monitored carefully during and after the transition period for signs of deterioration. Patients with clinical deterioration were returned promptly to epoprostenol. Placebo or SC treprostinil doses were titrated in response to symptoms. Time to adjudicated clinical deterioration was compared between treatment groups, and exercise capacity, symptoms of disease, and safety were assessed throughout the study. Results: Twenty-two patients were enrolled and completed the study. Seven of 8 patients (88%) withdrawn to placebo had clinical deterioration, while only 1 of 14 patients (7%) withdrawn to SC treprostinil had clinical deterioration (p = 0.00023 based on a treatment comparison of time to deterioration). Analyses of exercise capacity and symptoms strongly supported the efficacy of SC treprostinil in epoprostenol-treated patients. Adverse events consisted of painful infusion site reactions and anticipated prostacyclin side effects. Conclusions: SC treprostinil is effective in pulmonary arterial hypertension and prevents clinical deterioration and maintains functional status in patients transitioned from epoprostenol.

KW - Prostacyclin

KW - Pulmonary hypertension

KW - Withdrawal trial

UR - http://www.scopus.com/inward/record.url?scp=35448992075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35448992075&partnerID=8YFLogxK

U2 - 10.1378/chest.06-2118

DO - 10.1378/chest.06-2118

M3 - Article

VL - 132

SP - 757

EP - 763

JO - Chest

JF - Chest

SN - 0012-3692

IS - 3

ER -